Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 02, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals' US subsidiary, Glenmark Pharmaceuticals Inc., USA, is set to launch Eribulin Mesylate Injection (1mg/2mL, 0.5 mg/mL) in single-dose vials in the American market. Eribulin Mesylate is a generic injectable used in the treatment of metastatic breast cancer. The launch expands Glenmark's oncology injectable portfolio in the US generics space. This is part of the company's ongoing strategy to grow its US business through complex generics and injectables.
This product launch adds to Glenmark's US revenue stream in hard currency and strengthens its oncology injectable portfolio, potentially supporting growth in the US generics market, though single product contribution may be modest.